echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Gilead's Trop-2 antibody conjugate drug gains second indication

    Gilead's Trop-2 antibody conjugate drug gains second indication

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Gilead Sciences announced that the U.
    S.
    FDA has accelerated the approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand its scope of use for the treatment of locally advanced or metastatic urothelium Cancer patients.
    They have been treated with platinum-containing chemotherapy and PD-1 or PD-L1 inhibitors.
    This is Trodelvy’s second FDA approval this year.
    Last week it received full FDA approval for the treatment of triple-negative breast cancer.

    In 2020, approximately 580,000 people worldwide will be diagnosed with bladder cancer.
    Urothelial cancer accounts for 90% of all bladder cancers and can also occur in the renal pelvis, ureter, and urethra.
    After the failure of initial platinum-containing therapy, 80% of advanced patients will not respond to PD-1 or PD-L1 inhibitor therapy.

    Trop-2 is highly expressed in various human epithelial cancers, including breast cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, head and neck cancer and ovarian cancer.
    Trop-2 overexpression plays a key role in tumor growth.
    In addition, in several cancers such as breast cancer, the high expression of Trop-2 has also been found to be associated with more aggressive diseases and poor prognosis.

    Trodelvy is an antibody-conjugated drug composed of an antibody targeting Trop-2 and the active metabolite SN-38 of the chemotherapeutic drug irinotecan.
    It can deliver SN-38 into cancer cells by binding to Trop-2 protein.
    It is worth mentioning that Everest has the development rights of this innovative antibody conjugate drug in Greater China.
    It has been approved for Phase 3 clinical trials in China to treat metastatic triple-negative breast cancer and advanced urothelial cancer that have received at least 2 lines of previous treatment.

    This accelerated approval is based on the results of a single-arm phase 2 clinical trial.
    Among 112 patients who can be evaluated for efficacy, 27.
    7% of patients achieved remission, of which the complete remission rate was 5.
    4%.
    The median duration of response was 7.
    2 months (95% CI: 4.
    7-8.
    6).

    Note: The original text has been deleted

    Reference materials:

    [1] US FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer.
    Retrieved April 13, 2021, from

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.